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Abstract
This phase 1b/2, multicenter, open-label study evaluated ibrutinib plus durvalumab in
relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
Patients were treatedwith once-daily ibrutinib 560 mg plus durvalumab 10mg/kg every
2 weeks in 28-day cycles in phase 1b without dose-limiting toxicities, confirming the
phase 2 dosing. Sixty-one patients with FL (n = 27), germinal center B-cell (GCB) DLBCL
(n = 16), non-GCB DLBCL (n = 16), and unspecified DLBCL (n = 2) were treated. Overall
response rate (ORR) was 25% in all patients, 26% in patients with FL, 13% in patients
with GCB DLBCL, and 38% in patients with non-GCB DLBCL. Overall, median
progression-free survival was 4.6 months and median overall survival was 18.1 months;
both were longer in patients with FL than in patients with DLBCL. The most frequent
treatment-emergent adverse events (AEs) in patients with FL and DLBCL, respectively,
were diarrhea (16 [59%]; 16 [47%]), fatigue (12 [44%]; 16 [47%]), nausea (9 [33%];
12 [35%]), peripheral edema (7 [26%]; 13 [38%]), decreased appetite (8 [30%]; 11 [32%]),
neutropenia (6 [22%]; 11 [32%]), and vomiting (5 [19%]; 12 [35%]). Investigator-defined
immune-related AEs were reported in 12/61 (20%) patients. Correlative analyses were
conducted but did not identify any conclusive biomarkers of response. In FL, GCB
DLBCL, and non-GCB DLBCL, ibrutinib plus durvalumab demonstrated similar activity
to single-agent ibrutinib with the added toxicity of the PD-L1 blockade; the combination
resulted in a safety profile generally consistent with those known for each individual
agent.
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1 | INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are
the most common subtypes of non-Hodgkin lymphoma in adults.1-4
Although most patients respond to first-line chemoimmunotherapy, a
substantial proportion of patients with DLBCL andmost patients with FL
will eventually relapse or have refractory disease.1-5 The treatment of
relapsed/refractory DLBCL and FL remains challenging, with a minority
of patients with DLBCL achieving durable remission and patients with FL
experiencing decreased duration of remission with successive thera-
pies.1-5 Effective, well-tolerated therapy for relapsed/refractory DLBCL
and FL remains an unmet need.
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine
kinase (BTK), is approved in theUnited States, Europe, and other countries
for the treatment of various B-cell malignancies.6,7 In addition to BTK,
ibrutinib has also been shown to inhibit interleukin 2-inducible kinase,
resulting in suppression of Th2 cells and potentiation of Th1-mediated
immunity.8 Although ibrutinib has demonstrated clinically meaningful effi-
cacy against many B-cell malignancies, the ORR to ibrutinib alone for
patients with relapsed/refractory FL is approximately 21%-38% among
current studies, and theORR for patientswith relapsed/refractory DLBCL
receiving single-agent ibrutinib is 28%, motivating the investigation of
combination approaches to improve response.9-11
Programmed death (PD)-1, an inhibitory receptor expressed by acti-
vated T cells, limits autoimmunity by suppressing T cell–mediated immune
responses following engagement by its ligands, PD-L1 or PD-L2.12 Tumors
frequently exploit the PD-1 pathway to evade immune surveillance via
upregulation of PD-1 and/or PD-L1 expression on tumor cells and tumor-
associated immune cells.13Gene amplification of thePD-1 ligands andover-
expression of PD-L1 on tumor cells and tumor-associated macrophages is
present in certain subsets of patients with DLBCL,14,15 and PD-L1 expres-
sion is associated with poorer survival after standard therapy.16 High PD-1
expression on CD4+ tumor-infiltrating lymphocytes has been observed in
FL.17-19 Durvalumab is an anti–PD-L1 antibody that restores antitumor
immune responses.20 Other PD-1/PD-L1–targeted agents have demon-
strated antitumor activity in patients with DLBCL or FL.21-24 Notably, data
from murine lymphoma models suggest that ibrutinib combined with an
anti–PD-L1 antibody may have synergistic antitumor activity.25 Together,
the immune-modulating properties of ibrutinib, PD-1/PD-L1 expression
observed in patients with DLBCL and FL, and preclinical data suggesting
synergy between the agents provide a strong rationale for investigating the
combination of ibrutinibwith PD-1/PD-L1 blockade in FL andDLBCL.
We therefore performed a phase 1b/2 study to evaluate the
safety and antitumor activity of the combination of ibrutinib and
durvalumab in patients with relapsed/refractory DLBCL or FL.
2 | METHODS
2.1 | Patients
Key eligibility criteria included age ≥18 years; pathologically con-
firmed DLBCL, with subtype identified via gene expression or
immunohistochemistry tests, or FL (grade 1, 2, or 3A) according to
World Health Organization criteria; relapsed/refractory disease to at
least one line of therapy; measurable disease (≥1 lesion >1.5 cm in
longest dimension); adequate hematological function independent of
transfusion and growth factor support; adequate hepatic and renal
function; prothrombin time <1.5 times the upper limit of normal (ULN)
and activated partial thromboplastin time <1.5 times ULN; and East-
ern Cooperative Oncology Group performance status of 0 or 1. In the
phase 2 portion of the study within the DLBCL cohort, patients with
germinal center B-cell (GCB) and non-GCB subtypes were to be
enrolled in a 1:1 ratio.
2.2 | Study design, treatment, and oversight
This was an open-label, multicenter phase 1b/2 study conducted at
12 centers in the United States from May 2015 to February 2018.
The phase 1b portion of the study employed a 6 + 3 de-escalation
design to determine the recommended phase 2 dose of ibrutinib in
combination with durvalumab, with starting doses of ibrutinib 560 mg
and durvalumab 10 mg/kg in cohort 1. The first patient in each dose
cohort served as a sentinel patient who was observed for a period of
≥3 days to monitor for any unexpected acute or overlapping toxicities
before dosing of the next patient. If two of the first six patients expe-
rienced a dose-limiting toxicity (DLT) during cycle 1, an additional
three patients were to be enrolled. If ≤1 of six or ≤2 of nine patients
experienced a DLT, the dose level was to be defined as the rec-
ommended phase 2 dose. If ≥2 of six or ≥3 of nine DLTs were
observed, dose de-escalation cohorts (ibrutinib to 420 mg and/or
durvalumab to 3 mg/kg) were available to be opened. In the phase
2 portion of the study, patients were treated at the recommended
phase 2 dose as determined in phase 1b. In all cohorts, ibrutinib was
administered orally once daily for up to 3 years in combination with
durvalumab given intravenously on days 1 and 15 of each
28-day cycle for up to 12 cycles in the absence of progressive disease
(PD) or unacceptable toxicity.
This study was conducted according to principles of the Declaration
of Helsinki and the International Conference on Harmonisation Guide-
lines for Good Clinical Practice, The study was approved by the institu-
tional review boards, research ethics boards, or independent ethics
committees of participating institutions. All patients provided written
informed consent. This study was registered with ClinicalTrials.gov,
number NCT02401048.
2.3 | Outcomes and assessments
The primary endpoints of the phase 1b portion of the study were to
determine the recommended phase 2 dose of ibrutinib in combination
with durvalumab as well as safety and tolerability; secondary end-
points included overall response rate (ORR) and duration of response.
The primary endpoint of the phase 2 portion of the study was the
ORR; secondary endpoints included duration of response,
progression-free survival (PFS), overall survival (OS), safety, and
tolerability.
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Response evaluations were performed every three cycles until
cycle 12 and every six cycles thereafter. Response was assessed by
the investigator according to revised criteria for malignant lymphoma
described by the International Working Group for non-Hodgkin Lym-
phoma.26 Adverse events (AEs) were coded using the Medical Dictio-
nary for Regulatory Activities (version 20.0) and graded according to
the National Cancer Institute Common Terminology Criteria for AEs
(CTCAE), version 4.03. Treatment-emergent adverse events (TEAEs)
were defined as (1) any AE occurring after the start of study treatment
and within 30 days of the last dose of ibrutinib or within 90 days after
the last dose of durvalumab, (2) any study drug–related AE regardless
of start date, or (3) any AE present at baseline that worsens in severity
of frequency after the start of study treatment or is considered by the
investigator to be study drug-related. Treatment-related DLTs
followed guidelines provided in the CTCAE (version 4.03) and were
defined as (1) any grade 3 or higher nonhematologic AE or (2) clinically
relevant hematologic AE.
2.4 | Biomarker analysis
Samples including peripheral blood, tumor tissue, buccal swabs, and
other specimens, such as skin biopsies and fluid collected during the
study, were used for biomarker analysis. Tumor tissue PD-L1 expres-
sion was visualized via immunohistochemistry with Dako PD-L1 22C3
pharmDx kit (Cancer Genetics, Rutherford, NJ, USA) following the kit
instructions, with high PD-L1 expression defined as ≥50% positive
tumor cells.27,28 DNA was extracted for genomic testing using a
targeted next-generation sequencing panel, ACE Extended Cancer
Panel for DNA (Personalis, Menlo Park, CA, USA), which includes
more than 1400 genes involved in cancer biology and more than
200 cancer-related microRNAs to assess baseline tumor mutation load
and characterize somatic variants. Depending on tumor tissue avail-
ability, between 1 and 2 μg of tumor DNA was used as input material
for panel testing, which resulted in an average >500-fold coverage
over the extended DNA panel footprint.
Tumor mutation burden was limited to mutations that resulted in
changes in amino acids and was evaluated for correlations in patients
with complete response (CR), in nonevaluable (nonresponsive)
patients, or in patients with PD using a Wilcoxon rank-sum test. The
pharmacodynamics of durvalumab were assessed through measure-
ment of the reduction in levels of free soluble PD-L1 in serum using
an enzyme-linked immunosorbent assay.
2.5 | Statistical analysis
Efficacy and safety were evaluated in all patients who received ≥1
dose of any study treatment. ORR was evaluated as the proportion of
patients achieving a best overall response of CR or partial response
with two-sided 95% confidence intervals (CIs) based on exact bino-
mial distribution (Clopper-Pearson interval). Time to event endpoints
were estimated using the Kaplan-Meier method. Safety and tolerabil-
ity were analyzed using descriptive summaries.
The statistical design for both the FL and DLBCL cohorts in phase
2, including number of patients and responders, follows the statistical
framework of Simon's two-stage design.29 To ensure adequate statis-
tical power to determine a difference in ORR compared with single-
agent ibrutinib for the phase 2 portion of the study, a maximum of
39 FL patients and 34 DLBCL patients (at a 1:1 ratio for GCB and
non-GCB subtypes) were enrolled. Interim analysis was planned for
the first 19 response-evaluable patients in the FL cohort and for the
first nine response-evaluable patients in the DLBCL cohort. The
response-evaluable population was defined as all patients who
received ≥1 dose of any study treatment and provided ≥1 post-
baseline response assessment. Cohort discontinuation was to be con-
sidered if there were ≤6 of 19 responders in the FL cohort or ≤1 of
nine responders in the DLBCL cohort. However, assessment of bio-
markers or tumor measurements could support continued enrollment.
Enrollment continued while the first 19 FL and nine DLBCL patients
underwent efficacy assessment. Enrollment was discontinued following
interim analysis showing that stopping rules had been met. The primary
analysis was considered the final analysis and was conducted after all
patients had the opportunity to receive 12 cycles of durvalumab. The
study was completed on February 5, 2018.
3 | RESULTS
Beginning on May 11, 2015, 62 patients were enrolled, including
27 with FL and 35 with DLBCL (GCB, n = 17; non-GCB, n = 16;
unknown, n = 2). The median age in all patients was 60 years (range:
22-82), with a median of 57 years (range: 31-79) in FL patients,
68 years (range: 22-82) in GCB DLBCL patients, and 67 years (range:
39-82) in non-GCB DLBCL patients; most patients were male (62%)
and white (90%) (Table 1). The median time from initial diagnosis to
the first dose of study treatment was 26.1 months (range: 6.0-362.5).
Most patients (85%) had received ≥2 prior treatment regimens
(median: 2 regimens [range: 1-7]) and 52% had disease that was
refractory to the last prior regimen (Table 1).
Sixty-one patients received ≥1 dose of ibrutinib and 58 patients
received ≥1 dose of durvalumab; one enrolled patient did not receive
any study treatment. The most common reason for discontinuation of
study treatment was PD (Table S1). The median follow-up duration
was 17.3 months (range: 0.2-28.1) for all patients, 17.0 months (range:
1.8+−28.1) for patients with FL, and 17.5 months (range: 0.2-23.6) for
patients with DLBCL.
No DLTs were observed in the phase 1b portion of the study.
Therefore, the starting dose level of ibrutinib 560 mg once daily in
combination with durvalumab 10 mg/kg every 2 weeks was defined
as the recommended phase 2 dose level. These doses are the highest
approved single-agent dose for each study treatment.
3.1 | Best overall response
Among 61 patients who were treated, 15 patients had an objective
response (25%; 95% CI, 15-37). ORRs were 26% (7/27 patients; 95%
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CI, 11-46) in FL patients, 13% (2/16 patients; 95% CI, 2-38) in
patients with GCB DLBCL, and 38% (6/16 patients; 95% CI, 15-65)
in patients with non-GCB DLBCL (Figure 1A). CR was observed in one
(4%) FL patient, one (6%) GCB DLBCL patient, and five (31%) non-
GCB DLBCL patients. Partial response was observed in six (22%) FL
patients, one (6%) GCB DLBCL patient, and one (6%) non-GCB DLBCL
patient.
Among all patients with a best response of CR or partial response,
median duration of response was 11.3 months (95% CI, 5.5-not eval-
uable [NE]). Median duration of response was NE (95% CI, 5.5-NE) in
TABLE 1 Baseline demographic and disease characteristics
Characteristic
FL GCB DLBCL Non-GCB DLBCL All DLBCL All patients
n = 27 n = 16 n = 16 n = 34a n = 61b
Median age (range), years 57 (31-79) 68 (22-82) 67 (39-82) 67 (22-82) 60 (22-82)
Sex, n (%)
Male 17 (63) 12 (75) 8 (50) 21 (62) 38 (62)
Female 10 (37) 4 (25) 8 (50) 13 (38) 23 (38)
Race, n (%)
White 23 (85) 15 (94) 15 (94) 32 (94) 55 (90)
Black/African American 1 (4) 0 1 (6) 1 (3) 2 (3)
Unknown 3 (11) 1 (6) 0 1 (3) 4 (7)
ECOG performance status, n (%)
0 15 (56) 7 (44) 9 (56) 16 (47) 31 (51)
1 12 (44) 9 (56) 7 (44) 18 (53) 30 (49)
≥2 0 0 0 0 0
De novo DLBCL, n (%) NA 16 (100) 16 (100) 34 (100) NA
Bulky disease ≥5 cm, n (%)
Yes 10 (37) 7 (44) 7 (44) 14 (41) 24 (39)
No 14 (52) 6 (38) 7 (44) 14 (41) 28 (46)
Unknown 3 (11) 3 (19) 2 (13) 6 (18) 9 (15)
B symptoms, n (%)
Yes 9 (33) 3 (19) 4 (25) 7 (21) 16 (26)
No 18 (67) 12 (75) 12 (75) 26 (76) 44 (72)
Unknown 0 1 (6) 0 1 (3) 1 (2)
WHO grade of FL, n (%)
1 2 (7) NA NA NA NA
2 15 (56) NA NA NA NA
3A 10 (37) NA NA NA NA
3B 0 NA NA NA NA
Number of prior regimens, n (%)
1 6 (22) 2 (13) 1 (6) 3 (9) 9 (15)
≥2 21 (78) 14 (88) 15 (94) 31 (91) 52 (85)
Median number of prior regimens (range) 2.0 (1.0-4.0) 2.0 (1.0-4.0) 3.0 (1.0-7.0) 2.5 (1.0-7.0) 2.0 (1.0-7.0)
Disease status following completion of
last prior regimen, n (%)
Relapsed from CR 14 (52) 2 (13) 7 (44) 9 (26) 23 (38)
Relapsed from PR 2 (7) 1 (6) 2 (13) 4 (12) 6 (10)
Refractory (SD or PD) 11 (41) 13 (81) 7 (44) 21 (62) 32 (52)
Median time from initial diagnosis to
first dose (range), months
49.9 (9.8-362.5) 14.1 (6.0-104.1) 19.5 (7.3-86.7) 14.7 (6.0-104.1) 26.1 (6.0-362.5)
Abbreviations: CR, complete response; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma;
GCB, germinal center B-cell; NA, not applicable; PD, progressive disease; PR, partial response; SD, stable disease; WHO, World Health Organization.
aIncludes patients with GCB DLBCL, non-GCB DLBCL, and unspecified DLBCL.
bPatients who received ≥1 dose of study treatment.
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patients with GCB DLBCL, NE (95% CI, 2.5-NE) in those with
non-GCB DLBCL, and 11.3 months (95% CI, 8.3-NE) in patients with
FL (Figure 1B).
Among patients with FL on combination treatment who had tumor
measurements at baseline and at least one time point posttreatment,
19 of 26 (73%) patients exhibited a decrease in tumor size; 7 of
26 (27%) patients experienced reductions >50% (Figure S1). Of
18 treated patients with DLBCL who had tumor measurements at
baseline and at least one posttreatment time point, 10 (56%) exhibited
tumor size reduction; 8 of 18 (44%) patients had reductions >50%
(Figure S1).
3.2 | PFS and OS
Sixty-one patientswere included in this analysis. Overall, themedian PFS
was 4.6 months (95% CI, 2.6-7.8) and the median OS was 18.1 months
(95% CI, 7.8-NE). PFS and OS were longer in patients with FL compared
to those with DLBCL, with a median PFS of 10.2 months (95% CI,
4.7-13.1); median OS was NE (95% CI, 23.6-NE). GCB DLBCL patients
had a median PFS of 2.9 months (95% CI, 1.2-5.1) and a median OS of
5.5 months (95% CI, 3.2-13.2), and non-GCB DLBCL patients had a
median PFS of 4.1 months (95% CI, 1.2-10.1) and a median OS of
7.3 months (95% CI, 1.8-NE) (Figure 2). Twelve-month PFS was 39.2%
(95% CI, 18.8-59.1) in FL patients, 12.5% (95% CI, 2.1-32.8) in GCB
DLBCL patients, and 26.7% (95% CI, 8.3-49.6) in non-GCB DLBCL
patients.
3.3 | Biomarkers
Overall baseline tumor mutation load based on a targeted panel con-
sisting of approximately 1400 cancer-related genes was available for
13 patients with FL (median, 94 mutations [range, 65-103]) and seven
patients with DLBCL (median, 96 mutations [range, 69-153]). In these
patients, tumor mutational burden at baseline was not associated with
best response status or maximum tumor shrinkage in either FL or
DLBCL cohorts. In a small subset of patients with FL in whom tumor
tissue was available (n = 11), baseline somatic variants in the HIST1H1E
and CANT1 genes were correlated with increased tumor shrinkage
(n = 11) (Figure S2). Additionally, the P21R single nucleotide polymor-
phism (SNP) in the TNFRSF13C gene was correlated with clinical pro-
gression in non-GCB DLBCL patients (n = 7).
For all 41 patients with evaluable data, serum PD-L1 was suppressed
to below the limit of quantitation starting within 10 minutes of the first





















































































































F IGURE 1 Best response among patients with FL and DLBCL* (A) and duration of response among patients with complete or partial response (B).
CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B-cell; ORR, overall response rate; PR,
partial response; SD, stable disease. *Excludes two patients with unspecified DLBCL subtype
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regardless of response. At baseline, only one patient with evaluable
response had high (>50%) PD-L1 expression in tumor cells; this
patient had GCB DLBCL and a best response of PD. One non-GCB
DLBCL patient with a nonevaluable response also had high PD-L1
expression. No FL patients who were evaluable for response had >10%
PD-L1–positive tumor cells. Due to the small number of patients with
high PD-L1 at baseline, the association of PD-L1 expression with clinical
response could not be determined.
3.4 | Safety
Among the 61 patients who received ≥1 dose of study medication, the
median duration of exposure to ibrutinib was 3.8 months (range:
0.1-23.2) and median duration of exposure to durvalumab was
3.0 months (range: 0.0-10.6). The most common TEAEs were generally
grade 1/2 (Table 2). Atrial fibrillation, arthralgia, and anemia of any
grade each occurred in 10% of all patients. Grade 3/4 TEAEs were
reported in 34 (56%) patients; the most frequent (≥5%) grade 3/4
TEAEs were neutropenia (n = 13, 21%), dyspnea (n = 6, 10%), fatigue
(n = 5, 8%), atrial fibrillation (n = 4, 7%), peripheral edema (n = 4, 7%),
and rash maculopapular (n = 4, 7%) (Table 2). One FL patient had grade
5 multiple organ dysfunction syndrome. Serious TEAEs were reported
in 33 (54%) patients; the most common (≥2%) serious TEAEs were atrial
fibrillation (n = 4, 7%), and neutropenia, peripheral edema, pyrexia, cel-
lulitis, pneumonia, urinary tract infection, hypercalcemia, muscular
weakness, syncope, and dyspnea were reported in two patients (3%)
each. Ibrutinib was discontinued because of TEAEs not related to PD in
four patients (7%), including left ventricular failure, pneumonitis, periph-
eral edema, and autoimmune hepatitis, which occurred in one patient
(2%) each. Durvalumab was discontinued because of TEAEs not related
to PD in five patients (8%). The only TEAE leading to durvalumab dis-
continuation in ≥2 patients was pneumonitis (n = 2, 3%), with left ven-
tricular failure, autoimmune hepatitis, and alanine aminotransferase
increase occurring in one patient (2%) each.
FL (n = 27)
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F IGURE 2 Progression-free survival in patients with (A) FL and (B) DLBCL. Overall survival in in patients with (C) FL and (D) DLBCL. DLBCL, diffuse
large B-cell lymphoma; FL, follicular lymphoma; GCB, germinal center B-cell; PFS, progression-free survival; OS, overall survival. *Includes patients with
GCB DLBCL, non-GCB DLBCL, and unspecified DLBCL. “+” denotes censored observation [Color figure can be viewed at wileyonlinelibrary.com]
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Overall, investigator-defined immune-related AEs were reported
in 12 (20%) patients and were grade 3/4 in seven (11%) patients.
Immune-related AEs occurred in five of 27 (19%) patients with FL and
in seven of 34 (21%) patients with DLBCL. Immune-related AEs of
any grade occurring in ≥2 patients were rash maculopapular (n = 4,
7%), pneumonitis (n = 3, 5%), and dyspnea (n = 2, 3%).
4 | DISCUSSION
Ibrutinib has been shown to suppress regulatory T cells, increase acti-
vation of cytotoxic T cells, and enhance proinflammatory cytokine
secretion,9,30 all of which might be expected to provide a more favor-
able tumor microenvironment for response to PD-1/PD-L1–targeted
therapies. Despite this strong rationale for the combination of
ibrutinib with PD-1/PD-L1–targeted therapy and preclinical evidence
in murine lymphoma models for synergistic antitumor activity with
ibrutinib plus durvalumab,25 our phase 1b/2 study of ibrutinib 560 mg
once daily with durvalumab 10 mg/kg every 2 weeks met the early
efficacy stopping rule. This suggests that the antitumor activity of the
combination was similar to what would be expected with single-agent
ibrutinib therapy in patients with relapsed/refractory FL and DLBCL.
In patients with relapsed/refractory FL, the ORR of 26% with the
combination of ibrutinib plus durvalumab was similar to the ORR of 21%
observed with single-agent ibrutinib in patients with relapsed/refractory
FL in the phase 2 DAWN study9 and was slightly lower than the ORR of
38% observed with single-agent ibrutinib in a phase 2 consortium in
patients with relapsed/refractory FL.10 Although the ORR of 26% with
ibrutinib plus durvalumab was lower than the previously observed
response rate in a phase 1 study of single-agent nivolumab in patients
with relapsed/refractory FL (40%),23 a subsequent larger phase 2 study
of nivolumab in patients with relapsed/refractory FL demonstrated that
the ORR was only 4% (ClinicalTrials.gov, NCT02038946). The median
PFS of 10.2 months achieved by patients with FL on combination treat-
ment in this study, in which almost 80% of patients were on at least their
third line of treatment, was comparable to the median PFS of 1 year
reported for patients with FL on their third-line treatment.31
In patients with relapsed/refractory DLBCL, the ORR with the
combination of ibrutinib plus durvalumab was 38% for patients with
the non-GCB subtype and 13% for those with the GCB subtype.
These ORRs are consistent with those previously observed with
single-agent ibrutinib in a phase 1/2 study in patients with relapsed/
refractory DLBCL, which demonstrated ORRs of 37% in patients with
TABLE 2 Treatment-emergent AEs of all grades occurring in ≥15% of all patients
AE, n (%)
FL All DLBCL All
n = 27 n = 34a n = 61
All Grades Grade 3/4 All Grades Grade 3/4 All Grades Grade 3/4
Diarrhea 16 (59) 1 (4) 16 (47) 1 (3) 32 (52) 2 (3)
Fatigue 12 (44) 1 (4) 16 (47) 4 (12) 28 (46) 5 (8)
Nausea 9 (33) 0 12 (35) 1 (3) 21 (34) 1 (2)
Peripheral edema 7 (26) 1 (4) 13 (38) 3 (9) 20 (33) 4 (7)
Decreased appetite 8 (30) 0 11 (32) 1 (3) 19 (31) 1 (2)
Neutropenia 6 (22) 4 (15) 11 (32) 9 (26) 17 (28) 13 (21)
Vomiting 5 (19) 0 12 (35) 0 17 (28) 0
Upper respiratory tract infection 12 (44) 0 3 (9) 0 15 (25) 0
Cough 8 (30) 0 6 (18) 0 14 (23) 0
Dyspnea 6 (22) 2 (7) 8 (24) 4 (12) 14 (23) 6 (10)
Rash maculopapular 6 (22) 3 (11) 7 (21) 1 (3) 13 (21) 4 (7)
Back pain 6 (22) 1 (4) 5 (15) 0 11 (18) 1 (2)
Pyrexia 3 (11) 0 8 (24) 2 (6) 11 (18) 2 (3)
Constipation 3 (11) 0 7 (21) 0 10 (16) 0
Dry mouth 4 (15) 0 6 (18) 0 10 (16) 0
Hyperuricemia 5 (19) 1 (4) 5 (15) 1 (3) 10 (16) 2 (3)
Insomnia 4 (15) 0 6 (18) 0 10 (16) 0
Thrombocytopenia 4 (15) 0 6 (18) 2 (6) 10 (16) 2 (3)
Dizziness 3 (11) 1 (4) 6 (18) 0 9 (15) 1 (2)
Increased tendency to bruise 5 (19) 0 4 (12) 0 9 (15) 0
Muscle spasms 6 (22) 0 3 (9) 0 9 (15) 0
Abbreviations: AE, adverse event; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma.
aIncludes patients with GCB DLBCL, non-GCB DLBCL, and unspecified DLBCL.
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the activated B-cell subtype and 5% in those with the GCB subtype.32
The differential response rates between these subtypes is probably
explained by chronic active B-cell receptor signaling, which activates
the NF-ĸB pathway through BTK in non-GCB tumors but not in GCB
tumors.33 DLBCL of the non-GCB subtype might also be expected to
benefit to a greater extent from PD-1/PD-L1–targeted therapy, as
high PD-L1 expression is only observed in non-GCB subtypes.14,15
While single-agent PD-1 blockade has demonstrated antitumor activ-
ity in patients with relapsed/refractory DLBCL, cell-of-origin analyses
have not been conducted.21,23 In addition, despite the promising
activity observed in initial studies, a larger phase 2 study of nivolumab
in relapsed/refractory DLBCL demonstrated a response rate of only
10% (n = 121).24
Tumor mutation load was not found to correlate with best response
status or tumor shrinkage in either cohort based on a targeted panel of
approximately 1400 cancer-related genes. Further analysis with whole-
genome sequencing or whole-exome sequencing would be informative
for assessing global mutation load as it relates to response and tumor
shrinkage. Baseline somatic variants in two genes,CANT1 andHIST1H1E,
were correlated with tumor shrinkage in the FL cohort, and presence of
the P21R SNP in the TNFRSF13C gene was correlated with PD status in
the non-GCB DLBCL cohort. These correlations are based on small sam-
ple sizes and should not be considered true predictive biomarkers of
response to the study regimen. These data evaluating somatic mutations
associated with response are hypothesis generating, precluding defini-
tive conclusion and requiring further confirmation.While the association
of PD-L1 expression with response could not be determined in this
study, recentwork has demonstrated an association between expression
of PD-L1 and CR in DLBCL patients treated with combination ibrutinib
and nivolumab, an antibody to the PD-1 receptor.34 The difference in
results of the two studies could be attributed to potential differences in
the mechanism of action of durvalumab and nivolumab (ie, PD-L1 rather
than PD-1 blockade), differences in methodologies for PD-L1 detection
and definitions of elevated PD-L1 expression, or other differences in
study design. Further study of correlation between response and PD-L1
expression in FL patients may be worthwhile; however, the low anti-
tumor activity observed with PD-L1 blockade in FL might make such
studies difficult.
Overall, safety findings with the combination of ibrutinib plus
durvalumab were consistent with the known safety profiles of the
individual drugs, with no new safety signals identified. The combina-
tion demonstrated acceptable tolerability at the highest dose level
tested (ibrutinib 560 mg once daily in combination with durvalumab
10 mg/kg every 2 weeks), with no DLTs observed. No clinically mean-
ingful differences were observed in the safety profile of the combina-
tion between the FL and DLBCL groups other than those expected
due to disease type and duration of observation in the study.
Based on initial studies that suggested promising antitumor activity
with PD-1/PD-L1 blockade, we and others undertook studies to evalu-
ate the safety and activity of anti–PD-1/PD-L1–based combinations.
However, subsequent studies of anti–PD-1 monotherapy have demon-
strated that the single-agent response rate in FL and DLBCL is 10% or
lower (ClinicalTrials.gov, NCT02038946). Unfortunately, despite a
strong rationale and promising preclinical data, the combination of
ibrutinib and durvalumab demonstrated similar activity to single-agent
ibrutinib and was associated with the added toxicity of PD-L1 blockade,
although the safety profile of the combination was generally consistent
with those known for each individual agent. Thus, this combination does
not warrant further study in FL or DLBCL. As PD-1/PD-L1 combinations
continue to be evaluated in patients with non-Hodgkin lymphoma, it will
be critical to understand the biological basis for response to those agents
in order to identify target populations for further study.
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